Icelandic
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Lysine Trial in Adults With Diarrhoea

Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
Krækjan er vistuð á klemmuspjaldið
StaðaLokið
Styrktaraðilar
International Centre for Diarrhoeal Disease Research, Bangladesh

Lykilorð

Útdráttur

Diarrhea as of today is still a major problem in developing world with high morbidity. Though mortality in under-5 children has declined over the years, diarrhea was responsible for 2.5 million deaths per year in developing countries. A median of 3.2 episodes of diarrhea in under-5 children per child-year has been estimated in developing countries. In Bangladesh, the overall prevalence of diarrhea was estimated to be about 2% for the entire population. However, a recent survey in 2003 with urban slum mothers indicated that the prevalence of diarrhea ranged from 0.7-4.1% in six divisional cities with 0.7% in Dhaka slum areas. Malnutrition remains the major adverse prognostic indicator for diarrhea related morbidity, which emphasizes importance of nutrition in early management. Repeated episodes of diarrhea are a frequent cause and consequence of malnutrition. To improve diarrhea situation in Bangladesh and elsewhere, interventions are directed to reduce mortality and morbidity through improvement of breast-feeding practices, complementary feeding, sanitation, increase in measles immunization rates, micronutrient supplementation, and oral rehydration therapy.
L-lysine, an essential amino acid, is required for healthy growth, tissue repair and enzyme production. It is a protein-building block that strengthens and nourishes the structural, circulatory and immune systems. It is not produced by the body like other essential amino acids and must be obtained from the diet. Some natural food sources for L-lysine include Lima beans, kidney beans, potatoes, corn, red meat, fish and milk. The mean requirement of lysine in healthy human adults is about 30 mg/kg body weight/day or 50 mg/g protein intake. Studies have shown that lysine therapy improves immune status and is used as a therapeutic agent in herpes simplex viral infection. A double-blind randomized trial of L-lysine treatment found it to be an effective agent for significant reduction in occurrence, severity and healing time for recurrent herpes simplex viral infection. Lysine fortification increased the blood levels of complement 3 (C3), CD-4 and CD-8 T-cells as compared with controls. These two studies suggest that supplementation of lysine through food fortification enhances immunological status. A few recent studies have also shown an effect of lysine on diarrheal incidence and severity. An experimental model suggested inhibitory effect of L-lysine on incidence of diarrhea induced by stress and 5-hydroxytryptamine. A community trial among adults in Syria showed that the period prevalence and mean duration of diarrheal illness were significantly lower in the female participants who consumed lysine-fortified wheat bread compared to the control group as well as better immunological parameters such as C3c delta.
The proposed study will observe the impact of a daily dose of 2000 mg supplemental L-lysine for 6 months on diarrheal illness in an adult population of an urban slum area in Dhaka whose principal diet is based on cereals such as rice and or wheat. The daily protein and lysine availability from diets of Bangladeshi population has been calculated to be about 43g and 1883 mg respectively, compared to 113g and 7,598 mg respectively in the USA. This means that 2000 mg daily supplementation of L-lysine would not pose any detrimental effect, as the combined usual and supplemental intake will still be substantially lower compared to the intake in USA. However, as expected, the supplemental L-lysine may reduce the incidence and severity of diarrheal illness through improvement of the nutritional and immunological status of the study population.
The investigators propose to conduct a community-based, double-blind randomized controlled trial in Mirpur area of Dhaka city. Adults aged 18 to 45 years residing in the catchment area for at least the last six months will be eligible for the study. A total of 440 subjects (220 females) will be enrolled. The results of the proposed study will contribute to our existing knowledge of the effect of lysine on incidence and severity of diarrheal illness as well as on immune status. A positive impact of lysine supplementation on diarrheal illness may lead to a future strategic approach to the control of diarrhea as a global public health problem.

Dagsetningar

Síðast staðfest: 04/30/2014
Fyrst lagt fram: 05/17/2014
Áætluð skráning lögð fram: 05/19/2014
Fyrst sent: 05/20/2014
Síðasta uppfærsla lögð fram: 05/19/2014
Síðasta uppfærsla sett upp: 05/20/2014
Raunverulegur upphafsdagur náms: 11/30/2005
Áætlaður aðallokunardagur: 11/30/2006
Áætlaður dagsetningu rannsóknar: 11/30/2006

Ástand eða sjúkdómur

Diarrhea

Íhlutun / meðferð

Dietary Supplement: Supplementation

Dietary Supplement: placebo supplementation

Stig

-

Armhópar

ArmurÍhlutun / meðferð
Placebo Comparator: placebo supplementation
2000 mg placebo tablets/day
Dietary Supplement: placebo supplementation
Active Comparator: Supplementation
lysine 2000 mg tablets/day supplementation
Dietary Supplement: Supplementation

Hæfniskröfur

Aldur hæfur til náms 18 Years Til 18 Years
Kyn sem eru hæf til námsAll
Tekur við heilbrigðum sjálfboðaliðum
Viðmið

Inclusion Criteria:

Adults aged 18 to 45 years residing in the catchment area for at least the last six months

Útkoma

Aðal niðurstöður ráðstafanir

1. incidence/attack rate of diarrhea among the subjects over the six-month period of lysine supplementation [6 months]

Primary outcome variable will be a decrease in incidence/attack rate of diarrhea among the subjects over the six-month period of lysine supplementation.

Aðgerðir vegna aukaatriða

1. diarrheal duration and severity assessed by a clinical score [6 months]

Secondary outcome variables will include diarrheal duration and severity assessed by a clinical score. Changes in immunological parameters including C3, total T-cell population, T-cell subset (CD4, CD8), natural killer cells as well as C-reactive protein and hemoglobin over time will also be assessed as outcome variables

Skráðu þig á
facebook síðu okkar

Heillasta gagnagrunnur lækningajurtanna sem studdur er af vísindum

  • Virkar á 55 tungumálum
  • Jurtalækningar studdir af vísindum
  • Jurtaviðurkenning eftir ímynd
  • Gagnvirkt GPS kort - merktu jurtir á staðsetningu (kemur fljótlega)
  • Lestu vísindarit sem tengjast leit þinni
  • Leitaðu að lækningajurtum eftir áhrifum þeirra
  • Skipuleggðu áhugamál þitt og vertu vakandi með fréttarannsóknum, klínískum rannsóknum og einkaleyfum

Sláðu inn einkenni eða sjúkdóm og lestu um jurtir sem gætu hjálpað, sláðu jurt og sjáðu sjúkdóma og einkenni sem hún er notuð við.
* Allar upplýsingar eru byggðar á birtum vísindarannsóknum

Google Play badgeApp Store badge